TRAIL及其受体在膀胱癌中的表达及相关性研究

发布时间：2018-06-24 16:52

本文选题：TRAIL + 免疫组化　；参考：《兰州大学》2017年硕士论文

【摘要】：目的:观察肿瘤坏死因子相关诱导凋亡配体(TRAIL)及其受体DR4、DcR1在膀胱癌组织及正常膀胱粘膜中的表达,并探讨其与临床病理特征间的相关性。方法:1.收集2007年1月至2014年8月期间兰州大学第二医院临床和病理资料齐全的膀胱癌石蜡标本,采用免疫组织化学PV9001二步法检测64例膀胱癌石蜡标本及14例正常膀胱组织中的TRAIL、DR4、DcR1的表达。2.分析TRAIL、DR4、DcR1的表达与临床病理之间的关系。3.用Spearman等级相关分析TRAIL、DR4、DcR1三者的相关性。结果:1.TRAIL、DR4、DcR1均表达细胞膜和细胞浆中,核有部分染色。TRAIL、DR4、DcR1在膀胱肿瘤组织及癌旁组织中均有表达。TRAIL在64例膀胱癌组织中的表达为28例(43.75%),相比较14例正常组织中的表达为12例(85.71%),两者相比具有统计学差异(P0.05)。2.DR4在64例膀胱癌组织中的表达为29例(56.25%),相比较14例正常组织中的表达为10例(71.43%),两者相比具有统计学差异(P0.05)3.DcR1在64例膀胱癌组织中的表达为34例(53.125%),相比较14例正常组织中的表达为2例(14.29%),两者相比具有统计学差异(P0.05).4.TRAIL(P=0.039)、DR4(P=0.018)与病理分级有关,而与性别、年龄、临床分期、是否淋巴转移等其他病理等特征无关。在高分化膀胱癌中,TRAIL、DR4中等表达或高表达,在低分化膀胱癌,TRAIL、DR4无表达或低表达,两者对比具有统计学意义(P0.05)。5.DcR1(P=0.028)与病理分级有关,而与其他病理等特征无关。在高分化膀胱癌组织中,DcR1无表达或低表达,在低分化膀胱癌中,DcR1中等或高表达,两者对比有统计学意义。(P0.05)。6.使用SPSS 22.0软件包Spearman相关性分析得出TRAIL与DR4的表达呈正相关(R=0.263,P=0.036);TRAIL与DcR1的表达呈负相关(R=-0.281,P=0.025);DR4与DcR1表达呈负相关(R=-0.277,P=0.027)。结论:TRAIL、DR4、DcR1在膀胱癌组织及正常组织中的表达具有统计学差异;并且与病理分级具有一定的相关性,与其他临床病理特征无关。
[Abstract]:Aim: to investigate the expression of tumor necrosis factor-related apoptosis-inducing ligand (trail) and its receptor DR4 (DcR1) in bladder cancer and normal bladder mucosa, and to investigate the correlation between trail and clinicopathological features. Method 1: 1. From January 2007 to August 2014, paraffin wax specimens of bladder cancer were collected from the second Hospital of Lanzhou University, with complete clinical and pathological data. The expression of TRAILDR4 DcR1 in 64 cases of bladder cancer and 14 cases of normal bladder tissues was detected by immunohistochemical PV9001 two-step method. To analyze the relationship between the expression of DcR1 and clinicopathology. Spearman rank correlation analysis was used to analyze the correlation among TRAILDR4 and DcR1. Results: 1. TRAILDR4DcR1 expressed in cell membrane and cytoplasm. The expression of .TRAIL-DR4DcR1 in bladder tumor tissues and paracancerous tissues was 43.75% (28 / 64), compared with 12 cases (85.71%) in 14 normal tissues. There was statistical difference between them (P0.05) .2.DR4 The expression of DcR1 in 64 cases of bladder cancer was 29 cases (56.25%), compared with 14 cases of normal tissues, 10 cases (71.43%). There was statistical difference between the two cases (P0.05) 3.The expression of DcR1 in 64 cases of bladder cancer tissues was 34 cases (53.125%), compared with 14 cases of normal tissues, the expression of DcR1 in 64 cases of bladder cancer tissues was 34 cases (53.125%). There were two cases (14.29%), the difference was statistically significant (P0.05). 4. Trail (P0. 039) DR4 (P0. 018) was correlated with pathological grade. It was not related to sex, age, clinical stage, lymphatic metastasis and other pathological features. In well-differentiated bladder cancer, the expression of trillon DR4 was moderate or high, but not in poorly differentiated bladder cancer. There was statistical significance between the two groups (P0.05). 5. DcR1 (P0. 028) was correlated with pathological grade, but not with other pathological features. There was no or low expression of DcR1 in well-differentiated bladder cancer, but moderate or high expression in poorly differentiated bladder cancer. There was significant difference between the two groups (P0.05). Using Spearman correlation analysis of SPSS22.0 software package, it was found that the expression of trail and DR4 was positively correlated with that of DcR1 (R0. 263, P0. 036). The expression of trail and DcR1 was negatively correlated with the expression of DR4 and DcR1 (R0. 277P0. 027). Conclusion the expression of DcR1 in human bladder cancer tissues and normal tissues is statistically different, and it is correlated with the pathological grade, but not with other clinicopathological features.
【学位授予单位】：兰州大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.14

【相似文献】